To correlate the variable clinical features of oestrogen-receptor-positive breast cancer with
somatic alterations, we studied pretreatment tumour biopsies accrued from patients in two …

Resistance to oestrogen-deprivation therapy is common in oestrogen-receptor-positive
(ER+) breast cancer. To better understand the contributions of tumour heterogeneity and …

Aromatase inhibitors are the major first-line treatment of estrogen receptor–positive breast
cancer, but resistance to treatment is common. To date, no biomarkers have been validated …

Metastasis is the main cause of death for patients with breast cancer. Many studies have
characterized the genomic landscape of breast cancer during its early stages. However …

Breast carcinoma is the leading cause of cancer-related mortality in women worldwide, with
an estimated 1.38 million new cases and 458,000 deaths in 2008 alone. This malignancy …

The elucidation of breast cancer subgroups and their molecular drivers requires integrated
views of the genome and transcriptome from representative numbers of patients. We present …

We analysed primary breast cancers by genomic DNA copy number arrays, DNA
methylation, exome sequencing, messenger RNA arrays, microRNA sequencing and …

Learning Objectives After completing this course, the reader will be able to: Discuss the
published data on aromatase inhibitors in breast cancer. Describe the differences in study …

Genomic analysis of tumours has led to the identification of hundreds of cancer genes on the
basis of the presence of mutations in protein-coding regions. By contrast, much less is …

Tumor evolution is shaped by many variables, potentially involving external selective
pressures induced by therapies. After surgery, patients with estrogen receptor (ERα)-positive …